¾ÅÓÎÌåÓý

Journal News

Engineered fusion protein targets kiwifruit pathogen

Emily Ulrich
Aug. 6, 2025

The plant pathogen Pseudomonas syringae pv. actinidiae, or Psa, causes kiwifruit canker and contributes to larger issues of food shortage. Finding biocontrol agents that specifically target this pathogen would benefit agricultural production. Endolysin enzymes from bacteriophages have emerged as promising candidates. Endolysins cleave peptidoglycan, a layer of the cell wall in gram-positive bacteria. However, the gram-negative Psa has an outer membrane that shields the peptidoglycan inner layer. Suzanne Warring and Hazel Sisson at the University of Otago and a team of international scientists recently published their in the Journal of Biological Chemistry on developing an endolysin fusion protein active against Psa.

The authors used VersaTile molecular shuffling, a technique that created a library of phage proteins attached to endolysin. They performed a high-throughput screen for peptidoglycan-degrading activity and identified a lead compound that inhibited Psa growth. This hit compound, called ELP-E10, contains a lipase fused to endolysin, and the authors determined that the antibacterial activity relies on functional active sites for each fusion partner.

Notably, ELP-E10 shows specific activity for Psa, especially when combined with citric acid as a chemical permeabilizer. The researchers tested ELP-E10 activity against pathogens Pseudomonas aeruginosa and Staphylococcus aureus, as well as the commensal soil bacteria Pseudomonas fluorescens, and found that ELP-E10 shows specificity for Psa.

More experiments will help determine the exact outer membrane substrate that the lipase of ELP-E10 targets to allow the endolysin to reach the Psa peptidoglycan. These results suggest that endolysin fusion proteins could form promising antimicrobial candidates for agricultural use.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Emily Ulrich

Emily Ulrich is the ASBMB’s science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How sugars shape Marfan syndrome
Journal News

How sugars shape Marfan syndrome

Sept. 10, 2025

Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent ¾ÅÓÎÌåÓý paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent ¾ÅÓÎÌåÓý paper.